Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 6 Costs

From: Impact of an enhanced recovery pathway on length of stay and complications in elective radical cystectomy: a before and after cohort study

  Historical controls (N = 100) ERAS patients (N = 100) p value
Labs 2378.84 (1183.74) 2123.44 (1094.39) 0.0461
Radiology 1742.60 (2636.01) 723.96 (971.44) < 0.0011
Outpatient clinic 51.50 (106.67) 302.08 (251.84) < 0.0011
PT/OT/speech services 833.29 (958.07) 498.54 (454.28) < 0.0011
Pharmacy 5163.23 (5132.04) 3519.94 (2265.40) 0.0441
Surgery services 10,443.95 (4281.63) 10,954.26 (5739.40) 0.7001
Organ acquisition 2.62 (26.18) 94.34 (943.37) 1.0001
Blood products 1602.18 (1567.09) 930.27 (1056.96) < 0.0011
Cardiology services 256.10 (729.06) 114.49 (279.73) 0.0051
Respiratory care 1410.74 (4826.77) 168.77 (387.66) < 0.0011
Intensive care nursing services 6785.91 (9252.27) 3396.64 (5660.55) < 0.0011
Intermediate care nursing services 12,379.30 (9111.22) 8836.85 (5924.26) 0.0011
Medical/surgical supplies 708.80 (1548.63) 346.38 (641.13) < 0.0011
ER transport 18.41 (130.93) 8.22 (82.20) 0.5661
Other diagnostic and therapeutics 212.80 (704.33) 263.99 (1443.88) 0.0621
Other 0.00 (0.00) 19.69 (196.93) 0.3221
Total costs 43,990.26 (28,496.09) 32,301.85 (18,756.60) < 0.0011
  1. Continuous variables reported as mean (sd); all cost data reported in dollars
  2. 1Wilcoxon